Julphar To Expand Overseas

UAE generic drugmaker Julphar has revealed plans to invest US$152.6mn in expanding its business into manufacturing facilities specifically for insulins. The move underlines several trends in the country and region: the growing burden of diabetes is raising domestic demand which is, in turn, putting pressure on the government to either import more expensive preparations or source medicines locally. Another point is that domestic drug manufacturing across emerging markets is undergoing a period of expansion, particularly in the UAE, Egypt and Morocco, which highlights a drive for countries to be more competitive, self-reliant and to lower costs for the consumer.

To read the full article, please choose one of the following options: